Effectiveness of sitagliptin in Cystic Fibrosis with impaired glucose tolerance
Brief Description Of Study
Patients with Cystic Fibrosis often suffer from glucose intolerance. This study will evaluate how effective sitagliptin, a DPP-IV inhibitor, is at improving glycemic control in the Cystic Fibrosis population. Participants will complete baseline testing, then will be asked to take a once-daily pill for 6-months before completing follow-up testing. Participants are compensated $650 for completing study procedures.
Detailed Study Description
This trial will evaluate the participant's metabolic response pre- and post-treatment using a Mixed Meal Tolerance Test and a Glucose Potentiated Arginine Test. After successful Screening, patients will undergo metabolic testing on two separate days before starting study drug or placebo. After 6-months, participants will return for two days of follow-up testing. Participants are compensated $650 for time and inconvenience of Study Visits.
Additional Information About The Study
Please contact the Research Coordinator for with further questions or to schedule a Screening Visit: Jack Eiel email@example.com 215-746-2081